The Effect Of CD82and C-Met Combined Detection On Colorectal Cancer Liver Metastases

Objective: This study through Western blot and immunohistochemistryto observe the different expression of CD82and c-Met protein in primarytumors carcinoma tissue and the normal tissue adjacent to carcinoma tissue ofcolorectal cancer patients, with clinical and pathological data to explore theeffect of CD82and c-Met protein in colorectal cancer incidence, progression,invasion, and metastases.Methods: Select the primary tumor tissues and adjacent normal tissues(from the primary tumor cancers edge>10cm) of65patients with colorectalcancer after operation in the general surgery department of the FourthHospital of Hebei Medical University, using Western blot andimmunohistochemistry to detect the CD82and c-Met protein expression inprimary tumor tissues and adjacent normal tissues, with clinical andpathological data, analyze the differences in the expression of CD82andc-Met protein in colorectal cancer primary tumor tissues and normal tissues,meanwhile in liver metastasis group and without liver metastasis group,so asto explore the effect of CD82and c-Met protein in colorectal cancer incidence,progression, invasion, and metastases.Results：Among the primary tumor tissues of65cases of colorectalcancer patients, the positive rate of CD82protein was23.1%, in theadjacent normal tissues, the positive rate of CD82protein was63.1%, thedifference was statistically significant (P<0.01). In colorectal cancer with livermetastasis group, the positive rate of CD82protein was41.7%, in colorectalcancer without liver metastasis group, the positive rate of CD82proteinwas75.5%, the difference was statistically significant (P<0.05). In patientswith colorectal cancer TNM stage Ⅰt he positive rate of CD82protein was70.0%, Ⅱt he positive rate was61.1%, Ⅲt he positive rate was60.0%, Ⅳthe positive rate was16.7%, the overall positive rate difference was statisticallysignificant (P<0.05). In colorectal cancer with lymph node metastasis group,the positive rate of CD82protein was36.4%, in colorectal cancer withoutlymph node metastasis group, the positive rate was84.4%, the difference wasstatistically significant (P <0.01). The expression of CD82was not associatedwith the colorectal cancer patients’ gender, age, site of tumor growth, degreeof tumor invasion and differentiation, the difference was not statisticallysignificant (P>0.05).Among the primary tumor tissues of65cases ofcolorectal cancer patients, the positive rate of c-Met protein was58.5%, inthe adjacent normal tissues, the positive rate of c-Met protein was18.5%,the difference was statistically significant (P<0.01). In colorectal cancer withliver metastasis group, the positive rate of c-Met protein was91.7%, incolorectal cancer without liver metastasis group, the positive rate of c-Metprotein was47.2%, the difference was statistically significant (P<0.01).Expression of CD82and c-Met protein in patients with colorectal cancertissues showed a positive correlation (rs=-0.53, P=0.00).Conclusion:1CD82protein expression in tissue of colorectal cancer patients wassignificantly lower than in adjacent normal mucosa carcinoma,and with theprogress of pathologic stage, lymph node metastasis and liver metastasisCD82protein expression decreased.2In the tissue of the colorectal cancer patients with liver metastases,the expression of CD82was significantly reduced, while the expression ofc-Met protein significantly increased,the differences of the expressionbetween the two proteins may be Jointly promote the incidence andprogression of the liver metastases of colorectal cancer patients.3CD82and c-Met may be able to conduct as important predictiveand diagnostic indicators of tumor progression and metastases in patientswith colorectal cancer, joint detection of CD82and c-Met in patients withcolorectal cancer tissues may provide the basis for prediction and treatmentfor the diagnosis of colorectal cancer patients.